Chardan Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $14.00 target price on the stock. Chardan Capital’s target price suggests a potential upside of 101.15% from the stock’s previous close.

Coya Therapeutics Stock Down 6.6 %

COYA traded down $0.49 on Wednesday, hitting $6.96. The company had a trading volume of 66,416 shares, compared to its average volume of 75,339. The company has a market cap of $101.76 million, a PE ratio of -8.19 and a beta of 0.77. Coya Therapeutics has a 12-month low of $3.21 and a 12-month high of $10.69. The business’s fifty day simple moving average is $8.56 and its 200 day simple moving average is $7.78.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.35) EPS for the quarter. The company had revenue of $0.13 million during the quarter. On average, analysts anticipate that Coya Therapeutics will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Greenlight Capital Inc. boosted its position in shares of Coya Therapeutics by 172.2% during the fourth quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after buying an additional 805,959 shares during the period. Vanguard Group Inc. boosted its position in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares during the period. Finally, AIGH Capital Management LLC boosted its position in shares of Coya Therapeutics by 92.6% during the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after buying an additional 496,183 shares during the period. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.